How much funding has SynapDx raised?

SynapDx has raised $35.2M in total funding, most recently a Venture Round.

Who are SynapDx's investors?

SynapDx's investors include General Catalyst, GV, Bain Capital Ventures, Gershon Capital, North Bridge Venture P.

Where is SynapDx headquartered?

SynapDx is headquartered in Lexington, Massachusetts, United States.

What industry is SynapDx in?

SynapDx operates in Biotech, Diagnostics, Healthcare.

SynapDx

Closed

Blood-based diagnostics for earlier autism detection

Lexington, United States · Founded 2010 · $35.2M raised

Biotech

Diagnostics

Healthcare

Headquarters: Lexington, Massachusetts
Employees: 1–10
Founded: 2010
Business Model: B2B

Website: synapdx.com
Total Funding: $35.2M
Last Round: $35.2M Venture Round
Rounds: 1

About

SynapDx was a biotechnology company focused on developing blood-based diagnostic tests for the early detection of autism spectrum disorder (ASD). The company's proprietary platform used RNA-sequencing technology to evaluate gene expression levels and identify specific autism-related biological markers in a standard blood draw, enabling earlier and more objective screening compared to behavioral assessment alone. SynapDx collaborated with ASD experts at leading academic and clinical institutions to validate its approach. The company raised approximately $32.7 million across five funding rounds from investors including Google Ventures, North Bridge Venture Partners, General Catalyst Partners, LabCorp, Windham Venture Partners, Casdin Capital, Foundation Medical Partners, and The Kraft Group. SynapDx was ultimately deadpooled after its Series C in 2013, before achieving commercial launch.

Summary

SynapDx is a Biotech company based in Lexington, United States, founded in 2010. It has raised $35.2M in total across 1 round. Investors include General Catalyst, GV and Bain Capital Ventures.